Article
BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer.
Molecular and cellular biochemistry - 1 Sept 2021
Ohnami Shumpei, Maruyama Kouji, Chen Kai, Takahashi Yu, Hatakeyama Keiichi, Ohshima Keiichi, Shimoda Yuji, Sakai Ai, Kamada Fukumi, Nakatani Sou, Naruoka Akane, Ohnami Sumiko, Kusuhara Masatoshi, Akiyama Yasuto, Kagawa Hiroyasu, Shiomi Akio, Nagashima Takeshi, Urakami Kenichi, Yamaguchi Ken
Abstract excerpt
Despite the frequent detection of KRAS driver mutations in patients with colorectal cancer (CRC), no effective treatments that target mutant KRAS proteins have been introduced into clinical practice. In this study, we identified potential effector molecules, based on differences in gene expression between CRC patients carrying wild-type KRAS (n = 390) and those carrying KRAS mutations in codon 12 (n = 240). CRC...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.